Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Ordinary shares, par value NIS 0.10 per share
-
Shares outstanding
-
2.05B
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
2.51M
-
Shares change
-
+2.5M
-
Total reported value, excl. options
-
$6.63M
-
Value change
-
+$6.63M
-
Number of buys
-
11
-
Number of sells
-
-1
-
Price
-
$2.64
Significant Holders of BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) as of Q3 2019
12 filings reported holding BLRX - BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share as of Q3 2019.
BioLineRx Ltd. - Ordinary shares, par value NIS 0.10 per share (BLRX) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.51M shares
of 2.05B outstanding shares and own 0.12% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.73M shares), Senvest Management, LLC (503K shares), MORGAN STANLEY (145K shares), ORBIMED ADVISORS LLC (69.2K shares), ETF MANAGERS GROUP, LLC (47.7K shares), NEXT Financial Group, Inc (7.53K shares), VAN ECK ASSOCIATES CORP (3.69K shares), WELLS FARGO & COMPANY/MN (2.7K shares), UBS Group AG (1.08K shares), and Asset Dedication, LLC (366 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.